Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

An update from Passage Bio ( ($PASG) ) is now available. On August 12, 2025, Passage Bio reported its second quarter financial results and ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing ...

Emma Heming Willis took to her Instagram Stories on August 10 to share a fun fact about her husband, Bruce Willis. "You ever hear about those kinda guys who don't want their ladies wearing heels so ...

Targeting cellular structures called nuclear speckles could be a completely new approach for treating proteinopathies, ...

Researchers at Boston University Chobanian & Avedisian School of Medicine have built an artificial intelligence tool that can ...

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...

Targeting cellular structures called nuclear speckles could be a completely new approach for treating proteinopathies—diseases driven by abnormal accumulation of misfolded proteins—such as Alzheimer's ...

A groundbreaking study reveals that reshaping nuclear speckles — tiny structures inside cell nuclei that regulate protein maintenance — could be a novel way to treat proteinopathies like Alzheimer’s, ...

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...

PHILADELPHIA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...